Magnesium + Prochlorperazine for Migraine
(MAGraine2 Trial)

Recruiting in Palo Alto (17 mi)

Overseen byRyan McKillip, MD

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 3

Waitlist Available

Sponsor: Wake Forest University Health Sciences

No Placebo Group

Pivotal Trial (Near Approval)

Prior Safety Data

Trial Summary

What is the purpose of this trial?

The purpose of this research study is to find out if using magnesium in addition to prochlorperazine will help reduce your migraine pain.

Research Team

Ryan McKillip, MD

Principal Investigator

Wake Forest University Health Sciences

Eligibility Criteria

This trial is for adults over 18 who can consent, speak English, and have been diagnosed with migraines characterized by recurrent, one-sided, pounding headaches often with nausea. It's not for those allergic to the study drugs, with kidney issues, pregnant women or if they've taken the study drug within two days before joining.

Inclusion Criteria

Able to provide informed consent

I am 18 years old or older.

English speaking

See 1 more

Exclusion Criteria

Allergy or sensitivity to study drug

I have a history of kidney problems.

Consumption of study drug within 48 hours prior to enrollment

See 3 more

Treatment Details

Interventions

Magnesium (Electrolyte Supplement)

Trial OverviewResearchers are testing whether adding magnesium to prochlorperazine (a medication already used) provides better relief from migraine pain compared to using prochlorperazine alone. Participants will be randomly given either magnesium or a placebo alongside prochlorperazine.

Participant Groups

2Treatment groups

Experimental Treatment

Active Control

Group I: Study DrugExperimental Treatment1 Intervention

Prochlorperazine 10 mg followed by Magnesium 2 g

Group II: Control ArmActive Control1 Intervention

Prochlorperazine 10 mg followed by placebo